Please use this identifier to cite or link to this item:
https://hdl.handle.net/10316/107213
Title: | Chitosan Plus Compound 48/80: Formulation and Preliminary Evaluation as a Hepatitis B Vaccine Adjuvant | Authors: | Bento, Dulce Jesus, Sandra Lebre, Filipa Gonçalves, Teresa Borges, Olga |
Keywords: | compound 48/80; chitosan; nanoparticles; mast cell activator; vaccine adjuvant; nasal vaccination | Issue Date: | 9-Feb-2019 | Publisher: | MDPI | Project: | CENTRO-01-0145-FEDER-000008/BrainHealth2020 PTDC/MEC-GAS/30331/2017 SFRH/BD/65141/2009 info:eu-repo/grantAgreement/FCT/6817 - DCRRNI ID/UID/NEU/04539/2013/PT |
Serial title, monograph or event: | Pharmaceutics | Volume: | 11 | Issue: | 2 | Abstract: | Current vaccine research is mostly based on subunit antigens. Despite the better toxicity profile of these antigens they are often poorly immunogenic, so adjuvant association has been explored as a strategy to obtain a potent vaccine formulation. Recently, mast cell activators were recognized as a new class of vaccine adjuvants capable of potentiating mucosal and systemic immune responses. In this study, a co-adjuvanted delivery system was developed and characterized, combining the mast cell activator C48/80 with chitosan nanoparticles (Chi-C48/80 NPs), and the results were compared with plain chitosan nanoparticles. The adsorption of model antigens onto the NP surface as well as the biocompatibility of the system was not affected by the incorporation of C48/80 in the formulation. The stability of the nanoparticles was demonstrated by studying the variation of size and zeta potential at different times, and the ability to be internalized by antigen presenting cells was confirmed by confocal microscopy. Vaccination studies with hepatitis B surface antigen loaded Chi-C48/80 NPs validated the adjuvanticity of the delivery system, demonstrating for the first time a successful association between a mast cell activator and chitosan nanoparticles as a vaccine adjuvant for hepatitis B virus, applied to a nasal vaccination strategy. | URI: | https://hdl.handle.net/10316/107213 | ISSN: | 1999-4923 | DOI: | 10.3390/pharmaceutics11020072 | Rights: | openAccess |
Appears in Collections: | FMUC Medicina - Artigos em Revistas Internacionais I&D CNC - Artigos em Revistas Internacionais FFUC- Artigos em Revistas Internacionais |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Chitosan-plus-compound-4880-Formulation-and-preliminary-evaluation-as-a-hepatitis-B-vaccine-adjuvantPharmaceutics.pdf | 4.11 MB | Adobe PDF | View/Open |
SCOPUSTM
Citations
31
checked on Sep 2, 2024
WEB OF SCIENCETM
Citations
28
checked on Sep 2, 2024
Page view(s)
79
checked on Oct 2, 2024
Download(s)
33
checked on Oct 2, 2024
Google ScholarTM
Check
Altmetric
Altmetric
This item is licensed under a Creative Commons License